Firebrick Pharma (FRE) 주식 개요파이어브릭 파마는 호주에서 포비돈 요오드를 사용하기 위한 새로운 제형의 개발 및 상용화에 종사하고 있습니다. 자세히 보기FRE 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적0/6재무 건전성6/6배당0/6위험 분석수익이 USD$1m 미만입니다(A$411K)지난 3개월 동안 주가 변동성이 Australian 시장과 비교했을 때 매우 높았습니다.의미 있는 시가총액이 없습니다(A$11M)지난 1년 동안 주주가 희석되었습니다.모든 위험 점검 보기FRE Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW499,106 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG499,106 investors already sharing narrativesYour Fair ValueAU$Current PriceAU$0.0351.7k% 고평가 내재 할인율Est. Revenue$PastFuture-5m2m2016201920222025202620282031Revenue AU$410.7kEarnings AU$60.4kAdvancedSet Fair ValueView all narrativesFirebrick Pharma Limited 경쟁사Cann GroupSymbol: ASX:CANMarket cap: AU$6.5mInvex TherapeuticsSymbol: ASX:IXCMarket cap: AU$7.9mPercheron TherapeuticsSymbol: ASX:PERMarket cap: AU$5.3mECS Botanics HoldingsSymbol: ASX:ECSMarket cap: AU$8.0m가격 이력 및 성과Firebrick Pharma 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가AU$0.03552주 최고가AU$0.08452주 최저가AU$0.031베타0.851개월 변동-16.67%3개월 변동-46.15%1년 변동-42.62%3년 변동-82.05%5년 변동n/aIPO 이후 변동-93.40%최근 뉴스 및 업데이트Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Rick Legleiter was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • May 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$13.7m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Revenue is less than US$1m (AU$411k revenue, or US$297k). Market cap is less than US$10m (AU$13.7m market cap, or US$9.88m). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding).Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Rick Legleiter was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Apr 17Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.51692 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.51692 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 21,636,603 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,638,298 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Mar 31Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,914,893 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Oct 16Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.102 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.102 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,200,000 Price\Range: AUD 0.085 Transaction Features: Subsequent Direct Listing더 많은 업데이트 보기Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Rick Legleiter was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • May 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$13.7m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Revenue is less than US$1m (AU$411k revenue, or US$297k). Market cap is less than US$10m (AU$13.7m market cap, or US$9.88m). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding).Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Rick Legleiter was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Apr 17Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.51692 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.51692 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 21,636,603 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,638,298 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Mar 31Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,914,893 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Oct 16Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.102 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.102 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,200,000 Price\Range: AUD 0.085 Transaction Features: Subsequent Direct Listing공시 • Sep 29Firebrick Pharma Limited, Annual General Meeting, Nov 26, 2025Firebrick Pharma Limited, Annual General Meeting, Nov 26, 2025.공시 • Aug 30Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.4 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 22,222,222 Price\Range: AUD 0.063 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Aug 26+ 1 more updateFirebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.4 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 22,222,222 Price\Range: AUD 0.063 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Jun 26Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.195 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.195 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,095,238 Price\Range: AUD 0.063 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Mar 05Firebrick Pharma Limited announced that it expects to receive AUD 1.1 million in funding from Pharma Nutria N.a. (metro Manila Luzon), Inc.Firebrick Pharma Limited announce that it has secured an investment from Pharma Nutria N.A., Inc to issue 11,578,947 ordinary shares at a price of AUD 0.095 per share for gross proceeds of AUD 1,099,999.965 on March 4, 2025. The Shares are subject to a voluntary escrow of 12 months. The 11,578,947 Shares will represent 5.2% of all Firebrick shares outstanding and therefore PNAI will become a substantial shareholder in Firebrick.공시 • Oct 29Firebrick Pharma Limited, Annual General Meeting, Nov 27, 2024Firebrick Pharma Limited, Annual General Meeting, Nov 27, 2024.공시 • Oct 17Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1587 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1587 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,885,454 Price\Range: AUD 0.055 Discount Per Security: AUD 0 Transaction Features: Subsequent Direct Listing공시 • Sep 12+ 1 more updateFirebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 36,363,636 Price\Range: AUD 0.055Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.04 loss in FY 2023)Full year 2024 results: AU$0.007 loss per share (improved from AU$0.04 loss in FY 2023). Net loss: AU$1.18m (loss narrowed 83% from FY 2023).공시 • Sep 15Firebrick Pharma Limited Announces That Trial Statisticians Have Completed Their Efficacy Analysis of the Headline Results in the Phase 3 Trial of Nasodine® Nasal Spray as A Treatment for the Common ColdFirebrick Pharma Limited announced that trial statisticians have completed their efficacy analysis of the headline results in the Phase 3 trial of Nasodine® Nasal Spray as a treatment for the common cold. The analysis has shown that the trial did not meet its primary endpoint, which was the impact of Nasodine on overall cold severity (GSS) in subjects with a confirmed viral infection (ITTi). Based on the reported results, the placebo (sterile water) performed better than Nasodine. In the QoL (`quality-of-life') measure (functional impairment caused by a cold), the results were also in favour of the placebo in the ITTi. Similar enigmatic results were seen in other population subsets. The results provided to the Company are shown in the table titled: Trial Headline Results Summary. These results are compared in summary form with the previous (2019) Phase 3 trial in the table titled: Phase 3 Trial Comparisons on Key Endpoints. The 2019 trial used the same protocol and treatment regimen as the current (2022-23) trialand both trials were robust Phase 3 trials. The 2019 trial took place in Australia, so a comparison of the results with the current trial for Australian sites only has been undertaken (not shown in summary tables). In the 2019 trial, the GSS benefit of Nasodine in the viral-infected subjects (N=52) was 22.9% (p=0.048), but in the current trial, for Australian sites, the benefit was reversed, with the water placebo outperforming Nasodine by 22.7% in the ITTi (N=181), the result being statistically significant (p=0.024). The reported results also appear to conflict with the Company's recently reported Phase 2 COVID-19 trial, where Nasodine treatment led to 100% clearance of the SARS-CoV-2 virus from the nasal passages. That result was significantly better than the placebo (p=0.028), which was the same water placebo as used in the 2022-23 Phase 3 trial. The Company is concerned that the results are so confounding, unexpected and at odds with previous data that there may be a systematic error or other issue in the data, and a detailed analysis is now underway to try to identify any causes of such an error. To that end, the Company is working with the Contract Research Organisation (CRO) responsible for trial governance and other service providers to thoroughly investigate the trial results. At this time, there is no evidence that the placebo and Nasodine treatments were switched during production, distribution or treatment.Reported Earnings • Aug 30Full year 2023 earnings released: AU$0.04 loss per share (vs AU$0.033 loss in FY 2022)Full year 2023 results: AU$0.04 loss per share (further deteriorated from AU$0.033 loss in FY 2022). Net loss: AU$6.80m (loss widened 79% from FY 2022).공시 • Jul 22Firebrick Update on Administrative Appeals Tribunal ProcessFirebrick Pharma Limited announced that the scheduled conciliation meeting with the TGA (Therapeutic Goods Administration), which was moderated by the Administrative Appeals Tribunal (AAT) took place in Sydney on 19 July 2023. The meeting between the parties was cordial with a frank exchange on the issues relating to the approval of Nasodine Nasal Spray ("Nasodine"). Confidential discussions between the parties are ongoing and Firebrick is hopeful that an agreement on the approval of Nasodine can be reached. This announcement was authorized for release by Dr. Peter Molloy, Executive Chairman, Firebrick Pharma Limited.공시 • May 16Firebrick Pharma Limited, Annual General Meeting, Jun 20, 2023Firebrick Pharma Limited, Annual General Meeting, Jun 20, 2023, at 11:00 E. Australia Standard Time. Agenda: To consider the ratification of tranche 1 placement shares; to consider the issue of tranche 2 placement shares to related party Stephen Goodall; and to consider the issue of tranche 2 placement shares to related party Peter Molloy.Board Change • Mar 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Richard Treagus was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.주주 수익률FREAU PharmaceuticalsAU 시장7D12.9%6.1%0.2%1Y-42.6%-10.0%2.2%전체 주주 수익률 보기수익률 대 산업: FRE은 지난 1년 동안 -10%의 수익을 기록한 Australian Pharmaceuticals 산업보다 저조한 성과를 냈습니다.수익률 대 시장: FRE은 지난 1년 동안 2.2%를 기록한 Australian 시장보다 저조한 성과를 냈습니다.주가 변동성Is FRE's price volatile compared to industry and market?FRE volatilityFRE Average Weekly Movement17.5%Pharmaceuticals Industry Average Movement10.4%Market Average Movement9.7%10% most volatile stocks in AU Market17.0%10% least volatile stocks in AU Market4.0%안정적인 주가: FRE의 주가는 지난 3개월 동안 Australian 시장보다 변동성이 컸습니다.시간에 따른 변동성: Insufficient data to determine FRE의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트2012n/aPeter Molloyfirebrickpharma.com파이어브릭 파마는 호주에서 포비돈 요오드를 사용하기 위한 새로운 제형의 개발 및 상용화에 종사하고 있습니다. 이 회사는 나소딘이라는 이름으로 감기 치료를 위한 광범위한 항균 비강 스프레이를 제공합니다. 또한 미국과 싱가포르에서도 사업을 운영하고 있습니다.더 보기Firebrick Pharma Limited 기초 지표 요약Firebrick Pharma의 순이익과 매출은 시가총액과 어떻게 비교됩니까?FRE 기초 통계시가총액AU$10.55m순이익 (TTM)-AU$2.45m매출 (TTM)AU$410.70k25.7x주가매출비율(P/S)-4.3x주가수익비율(P/E)FRE는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표FRE 손익계산서 (TTM)매출AU$410.70k매출원가AU$217.82k총이익AU$192.88k기타 비용AU$2.64m순이익-AU$2.45m최근 보고된 실적Dec 31, 2025다음 실적 발표일해당 없음주당순이익(EPS)-0.0086총이익률46.96%순이익률-596.85%부채/자본 비율0%FRE의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/06 05:46종가2026/07/03 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Firebrick Pharma Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Rick Legleiter was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • May 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$13.7m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Revenue is less than US$1m (AU$411k revenue, or US$297k). Market cap is less than US$10m (AU$13.7m market cap, or US$9.88m). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding).
Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Rick Legleiter was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Apr 17Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.51692 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.51692 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 21,636,603 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,638,298 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Mar 31Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,914,893 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Oct 16Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.102 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.102 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,200,000 Price\Range: AUD 0.085 Transaction Features: Subsequent Direct Listing
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Rick Legleiter was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • May 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$13.7m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Revenue is less than US$1m (AU$411k revenue, or US$297k). Market cap is less than US$10m (AU$13.7m market cap, or US$9.88m). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding).
Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Rick Legleiter was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Apr 17Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.51692 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.51692 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 21,636,603 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,638,298 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Mar 31Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,914,893 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Oct 16Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.102 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.102 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,200,000 Price\Range: AUD 0.085 Transaction Features: Subsequent Direct Listing
공시 • Sep 29Firebrick Pharma Limited, Annual General Meeting, Nov 26, 2025Firebrick Pharma Limited, Annual General Meeting, Nov 26, 2025.
공시 • Aug 30Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.4 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 22,222,222 Price\Range: AUD 0.063 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Aug 26+ 1 more updateFirebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.4 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 22,222,222 Price\Range: AUD 0.063 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Jun 26Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.195 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.195 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,095,238 Price\Range: AUD 0.063 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Mar 05Firebrick Pharma Limited announced that it expects to receive AUD 1.1 million in funding from Pharma Nutria N.a. (metro Manila Luzon), Inc.Firebrick Pharma Limited announce that it has secured an investment from Pharma Nutria N.A., Inc to issue 11,578,947 ordinary shares at a price of AUD 0.095 per share for gross proceeds of AUD 1,099,999.965 on March 4, 2025. The Shares are subject to a voluntary escrow of 12 months. The 11,578,947 Shares will represent 5.2% of all Firebrick shares outstanding and therefore PNAI will become a substantial shareholder in Firebrick.
공시 • Oct 29Firebrick Pharma Limited, Annual General Meeting, Nov 27, 2024Firebrick Pharma Limited, Annual General Meeting, Nov 27, 2024.
공시 • Oct 17Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1587 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1587 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,885,454 Price\Range: AUD 0.055 Discount Per Security: AUD 0 Transaction Features: Subsequent Direct Listing
공시 • Sep 12+ 1 more updateFirebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 36,363,636 Price\Range: AUD 0.055
Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.04 loss in FY 2023)Full year 2024 results: AU$0.007 loss per share (improved from AU$0.04 loss in FY 2023). Net loss: AU$1.18m (loss narrowed 83% from FY 2023).
공시 • Sep 15Firebrick Pharma Limited Announces That Trial Statisticians Have Completed Their Efficacy Analysis of the Headline Results in the Phase 3 Trial of Nasodine® Nasal Spray as A Treatment for the Common ColdFirebrick Pharma Limited announced that trial statisticians have completed their efficacy analysis of the headline results in the Phase 3 trial of Nasodine® Nasal Spray as a treatment for the common cold. The analysis has shown that the trial did not meet its primary endpoint, which was the impact of Nasodine on overall cold severity (GSS) in subjects with a confirmed viral infection (ITTi). Based on the reported results, the placebo (sterile water) performed better than Nasodine. In the QoL (`quality-of-life') measure (functional impairment caused by a cold), the results were also in favour of the placebo in the ITTi. Similar enigmatic results were seen in other population subsets. The results provided to the Company are shown in the table titled: Trial Headline Results Summary. These results are compared in summary form with the previous (2019) Phase 3 trial in the table titled: Phase 3 Trial Comparisons on Key Endpoints. The 2019 trial used the same protocol and treatment regimen as the current (2022-23) trialand both trials were robust Phase 3 trials. The 2019 trial took place in Australia, so a comparison of the results with the current trial for Australian sites only has been undertaken (not shown in summary tables). In the 2019 trial, the GSS benefit of Nasodine in the viral-infected subjects (N=52) was 22.9% (p=0.048), but in the current trial, for Australian sites, the benefit was reversed, with the water placebo outperforming Nasodine by 22.7% in the ITTi (N=181), the result being statistically significant (p=0.024). The reported results also appear to conflict with the Company's recently reported Phase 2 COVID-19 trial, where Nasodine treatment led to 100% clearance of the SARS-CoV-2 virus from the nasal passages. That result was significantly better than the placebo (p=0.028), which was the same water placebo as used in the 2022-23 Phase 3 trial. The Company is concerned that the results are so confounding, unexpected and at odds with previous data that there may be a systematic error or other issue in the data, and a detailed analysis is now underway to try to identify any causes of such an error. To that end, the Company is working with the Contract Research Organisation (CRO) responsible for trial governance and other service providers to thoroughly investigate the trial results. At this time, there is no evidence that the placebo and Nasodine treatments were switched during production, distribution or treatment.
Reported Earnings • Aug 30Full year 2023 earnings released: AU$0.04 loss per share (vs AU$0.033 loss in FY 2022)Full year 2023 results: AU$0.04 loss per share (further deteriorated from AU$0.033 loss in FY 2022). Net loss: AU$6.80m (loss widened 79% from FY 2022).
공시 • Jul 22Firebrick Update on Administrative Appeals Tribunal ProcessFirebrick Pharma Limited announced that the scheduled conciliation meeting with the TGA (Therapeutic Goods Administration), which was moderated by the Administrative Appeals Tribunal (AAT) took place in Sydney on 19 July 2023. The meeting between the parties was cordial with a frank exchange on the issues relating to the approval of Nasodine Nasal Spray ("Nasodine"). Confidential discussions between the parties are ongoing and Firebrick is hopeful that an agreement on the approval of Nasodine can be reached. This announcement was authorized for release by Dr. Peter Molloy, Executive Chairman, Firebrick Pharma Limited.
공시 • May 16Firebrick Pharma Limited, Annual General Meeting, Jun 20, 2023Firebrick Pharma Limited, Annual General Meeting, Jun 20, 2023, at 11:00 E. Australia Standard Time. Agenda: To consider the ratification of tranche 1 placement shares; to consider the issue of tranche 2 placement shares to related party Stephen Goodall; and to consider the issue of tranche 2 placement shares to related party Peter Molloy.
Board Change • Mar 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Richard Treagus was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
